Abstract 194P
Background
Uterine cervix cancer is especially frequent in Bangladesh. External beam radiotherapy (EBRT) and brachytherapy (BT) are effective treatments for cervical cancer.
Methods
This experimental investigation was done with histopathologically proven (squamous cell carcinoma) locally progressed carcinoma cervix with no history of prior therapy who came to the Department of Oncology, BSMMU; Department of Radiation Oncology NICRH for treatment. This research comprised 60 patients who met inclusion/exclusion criteria. Using a non-probability sampling approach, we separated the patients into two groups (30 in arm A and 30 in arm B). Arm-A had simultaneous EBRT and HDR-ICRT (EBRT = 50–50. 4 Gy/25–28 Fr, HDR 7 Gy in 3 Fr during the 3rd, 4th, and 5th weeks), although EBRT and weekly cisplatin (40 mg/m2) were not administered on the day of HDR-ICRT. Arm-B received EBRT and weekly cisplatin (40 mg/m2) followed by HDR-ICRT. Both groups were assessed weekly (general and systemic examination). All participants of both treatment modalities were followed up at the 6th and 12th week and at the 6th month following treatment to assess response and toxicities, and treatment success was reported as tumour size decrease (RECIST criteria and imaging tests) Symptom remission and cure may cause anaemia, neutropenia, thrombocytopenia, jaundice, renal failure, diarrhoea, nausea, and vomiting, according to the National Cancer Institute's “Common Terminology Criteria for Adverse Events, v.4.03” Comparing local tumor control and early complications at 6-month follow-up.
Results
Patients were 50±8.5 when diagnosed. Most patients are low-to-middle-class. 6 months following therapy, arm A had 86.6% full remission while arm B had 83.3%. Overall, 85% responded. Bladder and rectal, cutaneous, mild intestinal, and hematologic problems were well-managed. Three patients in arm A and two in arm B suffered grade II bladder toxicity, whereas only two in arm A developed rectal grade II toxicity. Arm B lacked rectal toxicity.
Conclusions
Concurrent ICBT and pelvic EBRT are similarly effective in addressing locally advanced carcinoma cervix with comparable toxicities and reduce total treatment time, allowing more patients to be treated each year.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dhaka Medical College & Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract